Detalles de la búsqueda
1.
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.
Cancer Immunol Immunother
; 72(6): 1445-1460, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469096
2.
Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Future Oncol
; 18(39): 4385-4397, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36656547
3.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280658
4.
Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.
Ann Surg Oncol
; 28(7): 3501-3510, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33205334
5.
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Future Oncol
; 17(10): 1165-1184, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33583206
6.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28885881
7.
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Lancet Oncol
; 20(12): 1670-1680, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31601496
8.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31422028
9.
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
Br J Cancer
; 120(8): 791-796, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30880334
10.
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.
Cancer Immunol Immunother
; 68(3): 517-527, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30591959
11.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412456
12.
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
Cancer Immunol Immunother
; 67(12): 1853-1862, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30209589
13.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28729154
14.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27932067
15.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.
N Engl J Med
; 380(10): 990, 2019 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30855761
16.
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
J Neurooncol
; 133(2): 331-338, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28466250
17.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Lancet Oncol
; 17(7): 883-895, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27269741
18.
Durvalumab in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(9): 869-870, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29490170
19.
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
BMC Cancer
; 16: 176, 2016 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26935219
20.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25704439